De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Hangzhou Tigermed Consulting Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Hangzhou Tigermed Consulting heeft een totaal eigen vermogen van CN¥24.1B en een totale schuld van CN¥3.6B, wat de schuld-eigenvermogensverhouding op 14.9% brengt. De totale activa en totale passiva bedragen respectievelijk CN¥30.4B en CN¥6.3B. De EBIT Hangzhou Tigermed Consulting is CN¥1.5B waardoor de rentedekking -4.2 is. Het heeft contanten en kortetermijnbeleggingen van CN¥3.2B.

Belangrijke informatie

14.9%

Verhouding schuld/eigen vermogen

CN¥3.58b

Schuld

Rente dekkingsratio	-4.2x
Contant	CN¥3.22b
Aandelen	CN¥24.07b
Totaal verplichtingen	CN¥6.35b
Totaal activa	CN¥30.42b

Recente financiële gezondheidsupdates

Is Hangzhou Tigermed Consulting (SZSE:300347) A Risky Investment?

Jun 26

Recent updates

Hangzhou Tigermed Consulting Co., Ltd's (SZSE:300347) Share Price Could Signal Some Risk

Aug 21

Hangzhou Tigermed Consulting (SZSE:300347) Is Increasing Its Dividend To CN¥0.568

Jul 12

Is Hangzhou Tigermed Consulting (SZSE:300347) A Risky Investment?

Jun 26

An Intrinsic Calculation For Hangzhou Tigermed Consulting Co., Ltd (SZSE:300347) Suggests It's 35% Undervalued

Jun 07

Hangzhou Tigermed Consulting Co., Ltd Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Apr 28

Hangzhou Tigermed Consulting Co., Ltd (SZSE:300347) Stock Catapults 27% Though Its Price And Business Still Lag The Market

Apr 08

Hangzhou Tigermed Consulting's (SZSE:300347) Profits Appear To Have Quality Issues

Apr 04

Hangzhou Tigermed Consulting Co., Ltd Just Missed Earnings - But Analysts Have Updated Their Models

Apr 01

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( CN¥7.6B ) 300347 } overtreffen de korte termijn passiva ( CN¥5.3B ).

Langlopende schulden: De kortetermijnactiva 300347 ( CN¥7.6B ) overtreffen de langetermijnschulden ( CN¥1.0B ).

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: De netto schuld/eigen vermogen ratio ( 1.5% ) 300347 wordt als voldoende beschouwd.

Schuld verminderen: De schuld/eigen vermogen-ratio van 300347 is de afgelopen 5 jaar gedaald van 16.5% naar 14.9%.

Schuldendekking: De schuld van 300347 wordt goed gedekt door de operationele kasstroom ( 26.6% ).

Rentedekking: 300347 verdient meer rente dan het betaalt, dus de dekking van rentebetalingen is geen probleem.

Hangzhou Tigermed Consulting Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Belangrijke informatie

Recente financiële gezondheidsupdates

Is Hangzhou Tigermed Consulting (SZSE:300347) A Risky Investment?

Recent updates

New minor risk - Share price stability

Hangzhou Tigermed Consulting Co., Ltd to Report Q3, 2024 Results on Oct 29, 2024

Investor sentiment improves as stock rises 18%

Consensus EPS estimates fall by 12%

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Hangzhou Tigermed Consulting Co., Ltd's (SZSE:300347) Share Price Could Signal Some Risk

Hangzhou Tigermed Consulting (SZSE:300347) Is Increasing Its Dividend To CN¥0.568

Dividend increased to CN¥0.57

Hangzhou Tigermed Consulting Co., Ltd to Report First Half, 2024 Results on Aug 29, 2024

Is Hangzhou Tigermed Consulting (SZSE:300347) A Risky Investment?

Hangzhou Tigermed Consulting Co., Ltd Announces Executive Changes

An Intrinsic Calculation For Hangzhou Tigermed Consulting Co., Ltd (SZSE:300347) Suggests It's 35% Undervalued

Consensus EPS estimates increase by 15%

Consensus EPS estimates fall by 19%

Hangzhou Tigermed Consulting Co., Ltd, Annual General Meeting, May 24, 2024

Hangzhou Tigermed Consulting Co., Ltd Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Price target decreased by 9.0% to CN¥60.82

Hangzhou Tigermed Consulting Co., Ltd (SZSE:300347) Stock Catapults 27% Though Its Price And Business Still Lag The Market

Hangzhou Tigermed Consulting's (SZSE:300347) Profits Appear To Have Quality Issues

Consensus revenue estimates fall by 11%

Hangzhou Tigermed Consulting Co., Ltd Just Missed Earnings - But Analysts Have Updated Their Models

Hangzhou Tigermed Consulting Co., Ltd to Report Q1, 2024 Results on Apr 24, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Hangzhou Tigermed Consulting Co., Ltd Announces Final Dividend for the Year Ended December 31, 2023, Payable on 31 July 2024

Hangzhou Tigermed Consulting Co., Ltd Announces Executive Changes

Investor sentiment improves as stock rises 27%

Investor sentiment deteriorates as stock falls 15%

Price target decreased by 7.9% to CN¥72.81

Hangzhou Tigermed Consulting Co., Ltd to Report Fiscal Year 2023 Results on Mar 29, 2024

Price target decreased by 17% to CN¥79.10

New major risk - Share price stability

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Price target decreased by 7.5% to CN¥116

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New minor risk - Share price stability

Hangzhou Tigermed Consulting Co., Ltd. Announces Final Profit Distribution Plan Implementation (A Shares) for 2022, Payable on 07 July 2023

Hangzhou Tigermed Consulting Co. Ltd. Proposes Ordinary Final Dividend for the Year Ended December 31, 2022, Payable on 07 July 2023

Less than half of directors are independent

Hangzhou Tigermed Consulting Co., Ltd Announces Executive Changes

Price target decreased by 8.0% to CN¥128

Price target decreased by 8.5% to CN¥127

Hangzhou Tigermed Consulting Co., Ltd. (SZSE:300347) acquired Marti Farm d.o.o. za trgovinu i usluge.

Executive VP & Executive Director recently sold CN¥7.5m worth of stock

Co-Founder recently sold CN¥477m worth of stock

Price target decreased to CN¥135

Less than half of directors are independent

Price target decreased to CN¥135

Investor sentiment improved over the past week

Now 21% undervalued after recent price drop

Third quarter 2022 earnings: Revenues exceed analyst expectations

Hangzhou Tigermed Consulting Co., Ltd. Announces Chief Financial Officer Changes

Investor sentiment improved over the past week

Hangzhou Tigermed Consulting Co., Ltd. to Report Q3, 2022 Results on Oct 25, 2022

Hangzhou Tigermed Consulting Co., Ltd. Announces Change of Employee Supervisor of Committee

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Hangzhou Tigermed Consulting Co., Ltd. to Report First Half, 2022 Results on Aug 25, 2022

Price target increased to CN¥158

Investor sentiment improved over the past week

Hangzhou Tigermed Consulting Co., Ltd Announces Executive Changes

Investor sentiment improved over the past week

Hangzhou Tigermed Consulting Co., Ltd Announces 2021 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on 31 May 2022

Hangzhou Tigermed Consulting Co., Ltd Approves Final Dividend to for the Year Ended December 31, 2021

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Less than half of directors are independent

Hangzhou Tigermed Consulting Co., Ltd to Report Q1, 2022 Results on Apr 26, 2022

Consensus EPS estimates increase by 11%

Hangzhou Tigermed Consulting Co., Ltd Declares Final Dividend for the Year Ended December 31, 2021

Price target decreased to CN¥170

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to CN¥178

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Hangzhou Tigermed Consulting Co., Ltd (SZSE:300347) announces an Equity Buyback for CNY 500 million worth of its shares.